**To the Editor:** In the June 2008 issue of Emerging Infectious Diseases, McCann et al. ([@R1]) reported on serologic screening for *Neospora caninum* antibodies and reported a lack of serologic evidence for *Neospora* infection in humans in England, where prevalence of infection with the closely related parasite *Toxoplasma gondii* also is low. Only limited data are available on human exposure to *Neospora*. We investigated the seroprevalence of *N. caninum* in humans in France, where *Toxoplasma* spp. seroprevalence is high.

Our study comprised 500 serum samples from healthy women, followed at the Cochin--Port Royal University Hospital in 1997 within the framework of toxoplasmosis surveillance during pregnancy, and 400 serum samples from HIV-infected patients. All serum samples were submitted to anti-*Toxoplasma* antibody testing by using indirect immunofluorescence (IIF; Toxo-spot IFI; bioMérieux, Marcy l'Etoile, France) and ELISA (Platelia Toxo IgG and IgM; BioRad, Hercules, CA, USA). An in-house microplate IIF test previously validated in cattle was used for simultaneous detection of anti-*Neospora* and anti-*Toxoplasma* immunoglobulin (Ig) G on the same microplate. All samples were screened at dilutions of 1:20 and 1:80, as is usually done in anti-*Toxoplasma* IIF assays in humans. Correlation between the anti-*Toxoplasma* IIF commercial test and in-house IIF was excellent (kappa coefficient = 0.98) and allowed us to compare the antibody titers against both parasites. Forty (8%) samples from immunocompetent persons and 21 (4%) from immunocompromised persons yielded a weak fluorescence when diluted 1:20. All but 4 had significant titers of anti-*Toxoplasma* IgG (\>200 IU/mL in 77% of cases), which suggests low-level cross-reactions. Whereas titers of \>200 and \>320 are considered sufficient to diagnose neosporosis in dogs and cattle, respectively ([@R2]), positivity threshold was difficult to resolve in the absence of a positive human control. We decided on a positivity threshold of 1:80, which is similar to the threshold defined by others in further studies using an indirect fluorescence antibody test in humans ([@R3],[@R4]). None of the 500 samples from immunocompetent persons were positive for *Neospora* antibodies when assessed at a dilution of 1:80. Within the group of immunocompromised persons, 3 were positive for *Neospora* antibodies at a titer of 80, and 1 was positive at a titer of 160. Three of these 4 HIV-infected patients had high titers of anti-*Toxoplasma* IgG (\>2,000 IU/mL), suggesting *Toxoplasma* serologic reactivation. We found no evidence of *Neospora* infection or exposure in immunocompetent persons but could not exclude possible *Neospora* infection associated with *Toxoplasma* infection or reactivation in immunocompromised persons.

Taken together, our data agree with data from other studies conducted in European countries ([@R1],[@R5]), which suggest that neosporosis in healthy humans is unlikely. However, the *Neospora* spp. seropositivity of some HIV-infected patients, although weak compared with the level of seropositivity in cattle or dogs, could suggest circulation of the parasite within immunocompromised hosts, a hypothesis supported by Lobato et al. ([@R3]). However, our observation of a strong serologic reactivation against *T. gondii* in 3 of 4 patients with anti-*Neospora* titers \>80 mostly favors cross-reactivity involving homologous antigens of both parasites and nonspecific antibody binding from polyclonal stimulation of the immune system. Finally, one should keep in mind that the positive predictive value of a serologic test used in screening in low-prevalence populations is low. Large-scale studies are needed to more precisely determine the potential role of this parasite in immunodeficient humans and to isolate the parasite or detect *Neospora* DNA in such patients.
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